" class="no-js "lang="en-US"> Nona Biosciences Enters Collaboration Agreement with ExeVir Bio
Thursday, June 08, 2023

Breaking News

Mendus and NorthX Biologics to Enter into Strategic Cell Therapy Manufacturing Alliance Supported by New Investor Flerie SciTech Development Raises $2.73 Million in Oversubscribed Funding Round to Advance Clinical Trials for Cancer Treatment Amarna Therapeutics Announces Appointment of Dr. Henk Streefkerk as New CEO Aegis Life Awarded Grant to Develop DNA-encoded Antibodies Against Infectious Diseases New “AI Doctor” Predicts Hospital Readmission and Other Health Outcomes Axol Bioscience Collaborates with StrataStem to Deliver Stem Cell-Based ‘Clinical Trial in a Dish’ for Alzheimer’s Disease MedTech Innovator Asia Pacific Names 24 Startups to Annual Accelerator XNK Therapeutics Appoints Hugo Petit as Chief Financial Officer Bayer Strengthens Gene Therapy Portfolio With Lipid Nanoparticle Technology From Acuitas Therapeutics Abivax Appoints Ida Hatoum as Chief People Officer
Nona Biosciences Enters into Collaboration Agreement with ExeVir Bio | MTA

April 6 2023

Nona Biosciences Enters into Collaboration Agreement with ExeVir Bio

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge technology innovation and provider of integrated solutions from “Idea to IND” (I to I™ ), has announced it has entered into a collaboration agreement with ExeVir Bio. The collaboration aims to accelerate the development of innovative therapeutics for unmet needs in infectious diseases, harnessing the combined expertise and resources of both companies.

Jingsong Wang, MD, PhD, Chairman of Nona Biosciences, said, ” By combining our respective expertise in antibody engineering and the disease area, we are confident that this collaboration will yield groundbreaking discoveries and bring us closer to eradicating the most challenging infectious diseases.”

Dr. Torsten Mummenbrauer, CEO of ExeVir, added, ” The collaboration with Nona Biosciences will be an important support in our ongoing research on bringing new infectious diseases treatments to patients and will deliver additional options to ExeVir’s pipeline in infectious diseases.

  1. Mendus and NorthX Biologics to Enter into Strategic Cell Therapy Manufacturing Alliance Supported by New Investor Flerie

    News

     Read more
  2. SciTech Development Raises $2.73 Million in Oversubscribed Funding Round to Advance Clinical Trials for Cancer Treatment

    Clinical Trials

     Read more
  3. Amarna Therapeutics Announces Appointment of Dr. Henk Streefkerk as New CEO

    Appointments

     Read more
  4. Aegis Life Awarded Grant to Develop DNA-encoded Antibodies Against Infectious Diseases

    Diseases

     Read more
  5. New “AI Doctor” Predicts Hospital Readmission and Other Health Outcomes

    News

     Read more
More On